{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:48:39Z","timestamp":1755218919935,"version":"3.43.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Introduction and importance:<\/jats:title>\n            <jats:p>Pulmonary arterial hypertension (PAH) was first associated with stimulants use in the 1960s during an outbreak of amphetamine-like appetite suppressants (anorexigens). To date, various drugs and toxins have been correlated with PAH. Diagnosing PAH in nephrotic syndrome has always remained a challenge due to the overlap of signs and symptoms in clinical presentation between the two entities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation:<\/jats:title>\n            <jats:p>In this report, the authors present an interesting case of a 43-year-old male, diagnosed with nephrotic syndrome secondary to minimal change disease, as well as currently presenting with PAH secondary to amphetamine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical discussion and conclusion:<\/jats:title>\n            <jats:p>Patients with nephrotic syndrome and end-stage renal disease should be regularly followed up and evaluated for comorbidities, complications, as well as adverse events from pharmacological intervention. In patients with end-stage renal disease hypertension control is key, stimulant use can precipitate poor blood pressure control especially in pulmonary arteries resulting in PAH. PAH can result in right ventricular dysfunction and heart failure that can further exacerbate renal dysfunction and vice-versa in a vicious cycle, deteriorating patient condition and quality of life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ms9.0000000000000355","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T07:15:18Z","timestamp":1680506118000},"page":"1874-1877","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["An interesting case of pulmonary hypertension in nephrotic syndrome due to amphetamine use for attention-deficit hyperactivity disorder"],"prefix":"10.1097","volume":"85","author":[{"given":"Abat","family":"Khan","sequence":"first","affiliation":[{"name":"Departments ofaInternal Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-2708","authenticated-orcid":false,"given":"Aamer","family":"Ubaid","sequence":"additional","affiliation":[{"name":"Departments ofaInternal Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7360-9744","authenticated-orcid":false,"given":"Muhammad","family":"Hanif","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-1660","authenticated-orcid":false,"given":"Vikash","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"AMA School of Medicine, Makati, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Gohar","sequence":"additional","affiliation":[{"name":"Respiratory and Critical Care Medicine, University of Missouri Kansas City,Kansas City, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-0906","authenticated-orcid":false,"given":"Aashna","family":"Mehta","sequence":"additional","affiliation":[{"name":"University of Debrecen-Faculty of Medicine, Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dushyant","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"Respiratory and Critical Care Medicine, University of Missouri Kansas City,Kansas City, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhigan Babu","family":"Shrestha","sequence":"additional","affiliation":[{"name":"M Abdur Rahim Medical College, Dinajpur, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,5]]},"reference":[{"key":"R1-20250806","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.rmed.2006.11.022","article-title":"Diagnosis and management of pulmonary hypertension over the past 100 years","volume":"101","author":"van Wolferen","year":"2007","journal-title":"Respir Med"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.1.5743.265","article-title":"Drug-induced pulmonary hypertension?","volume":"1","author":"Follath","year":"1971","journal-title":"BMJ"},{"key":"R4-20250806","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0269881113482532","article-title":"Amphetamine, past and present \u2013 a pharmacological and clinical perspective","volume":"27","author":"Heal","year":"2013","journal-title":"J Psychopharmacol"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.tcam.2013.03.002","article-title":"Adderall\u00ae (Amphetamine-Dextroamphetamine) Toxicity","volume":"28","author":"Fitzgerald","year":"2013","journal-title":"Top Companion Anim Med"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.18295\/squmj.2016.17.01.007","article-title":"Cardiovascular complications of acute amphetamine abuse: Cross-sectional study","volume":"17","author":"Bazmi","year":"2017","journal-title":"SQUMJ"},{"key":"R7-20250806","first-page":"1283","article-title":"Pulmonale arteri\u00eble hypertensie door amfetaminen gebruikt als drugs of doping [Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping]","volume":"149","author":"van Wolferen","year":"2005","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/apm.13065","article-title":"Nephrotic syndrome and pulmonary hypertension as complications of intravenous drug abuse","volume":"128","author":"Mohan","year":"2020","journal-title":"APMIS"},{"key":"R9-20250806","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/j.lpm.2013.07.005","article-title":"Drugs induced pulmonary arterial hypertension","volume":"42","author":"Seferian","year":"2013","journal-title":"La Presse M\u00e9dicale"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1111\/bcp.15436","article-title":"Identifying new drugs associated with pulmonary arterial hypertension: a WHO pharmacovigilance database disproportionality analysis","volume":"88","author":"Hlavaty","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R11-20250806","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10741-017-9612-9","article-title":"Drug-induced pulmonary arterial hypertension: a review","volume":"22","author":"Garg","year":"2017","journal-title":"Heart Fail Rev"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0960327112468174","article-title":"Involvement of serotonin mechanism in methamphetamine-induced chronic pulmonary toxicity in rats","volume":"32","author":"Wang","year":"2013","journal-title":"Hum Exp Toxicol"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00408-020-00355-0","article-title":"Prevalence and mortality of pulmonary hypertension in ESRD: a systematic review and meta-analysis","volume":"198","author":"Schoenberg","year":"2020","journal-title":"Lung"},{"key":"R14-20250806","first-page":"427","article-title":"Pulmonary hypertension in chronic kidney disease","volume":"39","author":"Travers","year":"2021","journal-title":"Cardiol Clin"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijsu.2020.10.034","article-title":"The SCARE 2020 guideline: updating consensus surgical CAse REport (SCARE) guidelines","volume":"84","author":"Agha","year":"2020","journal-title":"Int J Surg"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"e13453","DOI":"10.1111\/eci.13453","article-title":"Pulmonary hypertension in connective tissue diseases, new evidence and challenges","volume":"51","author":"Vonk","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/ki.1978.159","article-title":"Nephrotic syndrome complicating connective tissue disease","volume":"14","author":"Richard J.","year":"1978","journal-title":"Kidney Int"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000000355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:30:35Z","timestamp":1754487035000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000000355","relation":{},"ISSN":["2049-0801"],"issn-type":[{"type":"electronic","value":"2049-0801"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"2022-10-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}